U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C46H73N4O9
Molecular Weight 826.0932
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 1

SHOW SMILES / InChI
Structure of Minopafant ion

SMILES

CCCCCCCCCCCCCCCCCCNC(=O)OC1CCN(CC1)C(=O)OC[C@H](COC(=O)N(CC2=[N+](CC)C=CC=C2)C(=O)C3=CC=CC=C3OC)OC

InChI

InChIKey=HGOAIWZFTWACBD-RRHRGVEJSA-O
InChI=1S/C46H72N4O9/c1-5-7-8-9-10-11-12-13-14-15-16-17-18-19-20-24-31-47-44(52)59-39-29-33-49(34-30-39)45(53)57-36-40(55-3)37-58-46(54)50(35-38-26-23-25-32-48(38)6-2)43(51)41-27-21-22-28-42(41)56-4/h21-23,25-28,32,39-40H,5-20,24,29-31,33-37H2,1-4H3/p+1/t40-/m1/s1

HIDE SMILES / InChI

Molecular Formula C46H73N4O9
Molecular Weight 826.0932
Charge 1
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

Minopafant (E5880) is a novel platelet activating factor receptor antagonist. Minopafant had been in phase II clinical trials by Eisai in Japan for the treatment of disseminated intravascular coagulation. However, this research has been discontinued.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
0.27 nM [IC50]
Conditions

Conditions

PubMed

PubMed

TitleDatePubMed
Effect of a platelet-activating factor receptor antagonist, E5880, on cerebral vasospasm after aneurysmal subarachnoid hemorrhage--open clinical trial to investigate efficacy and safety.
2001-04
Involvement of platelet-activating factor (PAF) in glutamate neurotoxicity in rat neuronal cultures.
1997-04-18
Inhibitory effects of the novel platelet activating factor receptor antagonist, 1-ethyl-2-[N-(2-methoxy)benzoyl-N-[(2R)-2-methoxy-3-(4- octadecylcarbamoyloxy) piperidinocarbonyloxypropyloxy]carbonyl] aminomethyl-pyridinium chloride, in several experimentally induced shock models.
1991-07
Patents

Patents

Sample Use Guides

Intravenous Minopafant administration (300 ug or 1200 ug twice daily) was begun within 4 days and continued for 14 days.
Route of Administration: Intravenous
In Vitro Use Guide
Curator's Comment: The cultured neurons were exposed to glutamate (1 mM) for 60 min. Twenty-four hours after this exposure, protective effect of E5880 against neuronal damage was tested.
Minopafant (E5880) was tested for its neuroprotective activity in primary neuronal cultures isolated from embryonic rat cerebral cortex. Protective effect was observed in cultures treated with E5880 (P < 0.01 at 10 nM E5880)
Substance Class Chemical
Created
by admin
on Wed Apr 02 16:58:13 GMT 2025
Edited
by admin
on Wed Apr 02 16:58:13 GMT 2025
Record UNII
R382T79GF8
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
Minopafant cation
Preferred Name English
Minopafant ion
Common Name English
Pyridinium, 1-ethyl-2-[[(2-methoxybenzoyl)[[(2R)-2-methoxy-3-[[[4-[[(octadecylamino)carbonyl]oxy]-1-piperidinyl]carbonyl]oxy]propoxy]carbonyl]amino]methyl]-
Systematic Name English
1-Ethyl-2-[[(2-methoxybenzoyl)[[(2R)-2-methoxy-3-[[[4-[[(octadecylamino)carbonyl]oxy]-1-piperidinyl]carbonyl]oxy]propoxy]carbonyl]amino]methyl]pyridinium
Systematic Name English
Code System Code Type Description
PUBCHEM
130991
Created by admin on Wed Apr 02 16:58:13 GMT 2025 , Edited by admin on Wed Apr 02 16:58:13 GMT 2025
PRIMARY
FDA UNII
R382T79GF8
Created by admin on Wed Apr 02 16:58:13 GMT 2025 , Edited by admin on Wed Apr 02 16:58:13 GMT 2025
PRIMARY
CAS
760911-49-7
Created by admin on Wed Apr 02 16:58:13 GMT 2025 , Edited by admin on Wed Apr 02 16:58:13 GMT 2025
PRIMARY
Related Record Type Details
SALT/SOLVATE -> PARENT
TARGET -> INHIBITOR
IONIC MOIETY
Related Record Type Details
ACTIVE MOIETY